Weight Loss in Parkinson's Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth

John D DiBaise, Michael D. Crowell, Erika M Driver-Dunckley, Shyamal Mehta, Charlene Hoffman-Snyder, Tanya Lin, Charles Howard Adler

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND OBJECTIVE: Weight loss and small intestinal bacterial overgrowth (SIBO) are common in Parkinson's disease (PD). We aimed to study the relationship between weight loss and SIBO in PD.

METHODS: This was a cross-sectional study with a prospective, interventional component. Consecutive patients seen in the PD clinic who agreed to participate underwent extensive history, movement exam, SIBO breath testing and answered questionnaires. A subset of those in the weight loss group were treated with rifaximin for 14 days and returned 3 months later for an assessment of their weight, GI symptoms, quality of life and SIBO status. All analyses were adjusted for age and disease duration.

RESULTS: Fifty-one patients participated in the study; 37 without weight loss and 14 with weight loss. Total energy intake including the distribution of macronutrient intake was similar between groups while physical activity was less in those with weight loss. PD severity scores did not differ between groups; however, PD-specific quality of life scores were significantly worse for the summary index and the subscales of emotional well-being, social support and communication. The prevalence of constipation, dyspepsia and abdominal pain/discomfort was higher in those with weight loss. The prevalence of SIBO was 14% in the weight loss group and was not different between groups. Eight PD patients with weight loss were treated with rifaximin; no significant change in GI symptoms, quality of life or weight was seen 3 months later.

CONCLUSION: Although a number of differences were identified in quality of life and gastrointestinal symptoms between groups with and without weight loss, SIBO was not associated with weight loss in patients with PD. Given the exploratory nature and small number of patients with weight loss, however, further study is suggested.

Original languageEnglish (US)
Pages (from-to)571-581
Number of pages11
JournalJournal of Parkinson's Disease
Volume8
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Parkinson Disease
Weight Loss
rifaximin
Quality of Life
Weights and Measures
Dyspepsia
Constipation
Energy Intake
Social Support
Abdominal Pain
Cross-Sectional Studies
History
Communication
Exercise

Keywords

  • gastrointestinal
  • Parkinson’s disease
  • rifaximin
  • small intestinal bacterial overgrowth
  • weight loss

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Weight Loss in Parkinson's Disease : No Evidence for Role of Small Intestinal Bacterial Overgrowth. / DiBaise, John D; Crowell, Michael D.; Driver-Dunckley, Erika M; Mehta, Shyamal; Hoffman-Snyder, Charlene; Lin, Tanya; Adler, Charles Howard.

In: Journal of Parkinson's Disease, Vol. 8, No. 4, 01.01.2018, p. 571-581.

Research output: Contribution to journalArticle

@article{346d7a1caaf84ff5b5c15d745f0e5e18,
title = "Weight Loss in Parkinson's Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth",
abstract = "BACKGROUND AND OBJECTIVE: Weight loss and small intestinal bacterial overgrowth (SIBO) are common in Parkinson's disease (PD). We aimed to study the relationship between weight loss and SIBO in PD.METHODS: This was a cross-sectional study with a prospective, interventional component. Consecutive patients seen in the PD clinic who agreed to participate underwent extensive history, movement exam, SIBO breath testing and answered questionnaires. A subset of those in the weight loss group were treated with rifaximin for 14 days and returned 3 months later for an assessment of their weight, GI symptoms, quality of life and SIBO status. All analyses were adjusted for age and disease duration.RESULTS: Fifty-one patients participated in the study; 37 without weight loss and 14 with weight loss. Total energy intake including the distribution of macronutrient intake was similar between groups while physical activity was less in those with weight loss. PD severity scores did not differ between groups; however, PD-specific quality of life scores were significantly worse for the summary index and the subscales of emotional well-being, social support and communication. The prevalence of constipation, dyspepsia and abdominal pain/discomfort was higher in those with weight loss. The prevalence of SIBO was 14{\%} in the weight loss group and was not different between groups. Eight PD patients with weight loss were treated with rifaximin; no significant change in GI symptoms, quality of life or weight was seen 3 months later.CONCLUSION: Although a number of differences were identified in quality of life and gastrointestinal symptoms between groups with and without weight loss, SIBO was not associated with weight loss in patients with PD. Given the exploratory nature and small number of patients with weight loss, however, further study is suggested.",
keywords = "gastrointestinal, Parkinson’s disease, rifaximin, small intestinal bacterial overgrowth, weight loss",
author = "DiBaise, {John D} and Crowell, {Michael D.} and Driver-Dunckley, {Erika M} and Shyamal Mehta and Charlene Hoffman-Snyder and Tanya Lin and Adler, {Charles Howard}",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JPD-181386",
language = "English (US)",
volume = "8",
pages = "571--581",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Weight Loss in Parkinson's Disease

T2 - No Evidence for Role of Small Intestinal Bacterial Overgrowth

AU - DiBaise, John D

AU - Crowell, Michael D.

AU - Driver-Dunckley, Erika M

AU - Mehta, Shyamal

AU - Hoffman-Snyder, Charlene

AU - Lin, Tanya

AU - Adler, Charles Howard

PY - 2018/1/1

Y1 - 2018/1/1

N2 - BACKGROUND AND OBJECTIVE: Weight loss and small intestinal bacterial overgrowth (SIBO) are common in Parkinson's disease (PD). We aimed to study the relationship between weight loss and SIBO in PD.METHODS: This was a cross-sectional study with a prospective, interventional component. Consecutive patients seen in the PD clinic who agreed to participate underwent extensive history, movement exam, SIBO breath testing and answered questionnaires. A subset of those in the weight loss group were treated with rifaximin for 14 days and returned 3 months later for an assessment of their weight, GI symptoms, quality of life and SIBO status. All analyses were adjusted for age and disease duration.RESULTS: Fifty-one patients participated in the study; 37 without weight loss and 14 with weight loss. Total energy intake including the distribution of macronutrient intake was similar between groups while physical activity was less in those with weight loss. PD severity scores did not differ between groups; however, PD-specific quality of life scores were significantly worse for the summary index and the subscales of emotional well-being, social support and communication. The prevalence of constipation, dyspepsia and abdominal pain/discomfort was higher in those with weight loss. The prevalence of SIBO was 14% in the weight loss group and was not different between groups. Eight PD patients with weight loss were treated with rifaximin; no significant change in GI symptoms, quality of life or weight was seen 3 months later.CONCLUSION: Although a number of differences were identified in quality of life and gastrointestinal symptoms between groups with and without weight loss, SIBO was not associated with weight loss in patients with PD. Given the exploratory nature and small number of patients with weight loss, however, further study is suggested.

AB - BACKGROUND AND OBJECTIVE: Weight loss and small intestinal bacterial overgrowth (SIBO) are common in Parkinson's disease (PD). We aimed to study the relationship between weight loss and SIBO in PD.METHODS: This was a cross-sectional study with a prospective, interventional component. Consecutive patients seen in the PD clinic who agreed to participate underwent extensive history, movement exam, SIBO breath testing and answered questionnaires. A subset of those in the weight loss group were treated with rifaximin for 14 days and returned 3 months later for an assessment of their weight, GI symptoms, quality of life and SIBO status. All analyses were adjusted for age and disease duration.RESULTS: Fifty-one patients participated in the study; 37 without weight loss and 14 with weight loss. Total energy intake including the distribution of macronutrient intake was similar between groups while physical activity was less in those with weight loss. PD severity scores did not differ between groups; however, PD-specific quality of life scores were significantly worse for the summary index and the subscales of emotional well-being, social support and communication. The prevalence of constipation, dyspepsia and abdominal pain/discomfort was higher in those with weight loss. The prevalence of SIBO was 14% in the weight loss group and was not different between groups. Eight PD patients with weight loss were treated with rifaximin; no significant change in GI symptoms, quality of life or weight was seen 3 months later.CONCLUSION: Although a number of differences were identified in quality of life and gastrointestinal symptoms between groups with and without weight loss, SIBO was not associated with weight loss in patients with PD. Given the exploratory nature and small number of patients with weight loss, however, further study is suggested.

KW - gastrointestinal

KW - Parkinson’s disease

KW - rifaximin

KW - small intestinal bacterial overgrowth

KW - weight loss

UR - http://www.scopus.com/inward/record.url?scp=85055144407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055144407&partnerID=8YFLogxK

U2 - 10.3233/JPD-181386

DO - 10.3233/JPD-181386

M3 - Article

C2 - 30149465

AN - SCOPUS:85055144407

VL - 8

SP - 571

EP - 581

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 4

ER -